HC Wainwright Analysts Boost Earnings Estimates for CORT

Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) - Stock analysts at HC Wainwright lifted their Q4 2025 earnings per share estimates for shares of Corcept Therapeutics in a research note issued on Thursday, February 27th. HC Wainwright analyst S. Ramakanth now forecasts that the biotechnology company will post earnings of $0.73 per share for the quarter, up from their previous estimate of $0.70. HC Wainwright has a "Buy" rating and a $115.00 price objective on the stock. The consensus estimate for Corcept Therapeutics' current full-year earnings is $1.36 per share. HC Wainwright also issued estimates for Corcept Therapeutics' FY2029 earnings at $8.52 EPS.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last released its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $0.26 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.37 by ($0.11). The firm had revenue of $181.89 million for the quarter, compared to the consensus estimate of $200.12 million. Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%.

CORT has been the topic of several other research reports. StockNews.com lowered Corcept Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday. Piper Sandler raised their price objective on shares of Corcept Therapeutics from $67.00 to $78.00 and gave the stock an "overweight" rating in a research report on Thursday, February 27th. Finally, Canaccord Genuity Group lifted their price objective on shares of Corcept Therapeutics from $78.00 to $130.00 and gave the company a "buy" rating in a research note on Thursday, January 30th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $99.75.

Remove Ads

Corcept Therapeutics Trading Down 5.2 %

CORT traded down $3.08 during trading on Friday, reaching $55.99. 1,886,450 shares of the stock traded hands, compared to its average volume of 1,005,099. The stock's 50-day moving average is $60.12 and its 200 day moving average is $51.82. Corcept Therapeutics has a 12 month low of $20.84 and a 12 month high of $75.00. The company has a quick ratio of 3.64, a current ratio of 3.70 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $5.91 billion, a PE ratio of 44.44 and a beta of 0.58.

Insider Buying and Selling

In related news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the firm's stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $59.46, for a total value of $130,812.00. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Sean Maduck sold 20,000 shares of Corcept Therapeutics stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $50.39, for a total value of $1,007,800.00. Following the sale, the insider now directly owns 85,318 shares of the company's stock, valued at approximately $4,299,174.02. This trade represents a 18.99 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 26,600 shares of company stock valued at $1,399,576. 20.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of CORT. Kestra Investment Management LLC purchased a new position in Corcept Therapeutics in the 4th quarter worth about $27,000. Capital Performance Advisors LLP bought a new stake in shares of Corcept Therapeutics in the third quarter worth approximately $25,000. Canada Pension Plan Investment Board purchased a new position in shares of Corcept Therapeutics during the fourth quarter valued at approximately $40,000. National Bank of Canada FI bought a new position in Corcept Therapeutics during the fourth quarter valued at approximately $42,000. Finally, USA Financial Formulas purchased a new stake in Corcept Therapeutics in the fourth quarter worth approximately $54,000. 93.61% of the stock is owned by hedge funds and other institutional investors.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.